Catabasis Pharmaceuticals Inc (NASDAQ:CATB)‘s stock had its “outperform” rating reiterated by research analysts at Wedbush in a research note issued to investors on Monday. They currently have a $4.00 price objective on the stock. Wedbush’s price target would suggest a potential upside of 175.86% from the company’s previous close.

Several other analysts have also commented on the company. Cowen and Company lowered Catabasis Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $4.00 price target on the stock. in a research note on Wednesday, February 1st. Citigroup Inc lowered Catabasis Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Wednesday, February 1st. Zacks Investment Research raised Catabasis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, March 2nd. Oppenheimer Holdings Inc. set a $11.00 price target on Catabasis Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, January 31st. Finally, HC Wainwright initiated coverage on Catabasis Pharmaceuticals in a research note on Thursday, December 22nd. They issued a “buy” rating and a $14.00 price target on the stock. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $9.00.

Analyst Recommendations for Catabasis Pharmaceuticals (NASDAQ:CATB)

Shares of Catabasis Pharmaceuticals (NASDAQ:CATB) traded down 6.45% during trading on Monday, reaching $1.45. 1,244,376 shares of the company’s stock traded hands. Catabasis Pharmaceuticals has a 1-year low of $1.08 and a 1-year high of $7.89. The company has a 50 day moving average of $1.54 and a 200-day moving average of $3.55. The company’s market capitalization is $27.05 million.

This article was originally published by and is the sole property of American Banking News. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/03/20/catabasis-pharmaceuticals-catb-outperform-rating-reiterated-at-wedbush.html

Your IP Address:

A number of institutional investors have recently modified their holdings of the stock. Tocqueville Asset Management L.P. acquired a new position in shares of Catabasis Pharmaceuticals during the third quarter valued at about $123,000. Gilder Gagnon Howe & Co. LLC acquired a new position in shares of Catabasis Pharmaceuticals during the third quarter valued at about $138,000. TLP Group LLC acquired a new position in shares of Catabasis Pharmaceuticals during the third quarter valued at about $160,000. Federated Investors Inc. PA increased its position in shares of Catabasis Pharmaceuticals by 45.1% in the fourth quarter. Federated Investors Inc. PA now owns 160,000 shares of the company’s stock valued at $578,000 after buying an additional 49,750 shares during the last quarter. Finally, Alyeska Investment Group L.P. increased its position in shares of Catabasis Pharmaceuticals by 13.5% in the fourth quarter. Alyeska Investment Group L.P. now owns 223,885 shares of the company’s stock valued at $808,000 after buying an additional 26,685 shares during the last quarter. Hedge funds and other institutional investors own 61.43% of the company’s stock.

Catabasis Pharmaceuticals Company Profile

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

5 Day Chart for NASDAQ:CATB

Receive News & Ratings for Catabasis Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.